Cytolytic activity against allogeneic human endothelia: Resistance of cytomegalovirus-infected cells and virally activated lysis of uninfected cells

Transplantation

Volumn 66, Issue 1, 1998, Pages 67-77

  Waldman, W James ^a   Knight, Deborah A ^a   Adams, Patrick W ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS INFECTION; GRAFT INFECTION; HUMAN; HUMAN CELL; NONHUMAN; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VIRUS CELL INTERACTION; VIRUS INFECTION;

CELL DIVISION; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROGEN PEROXIDE; KILLER CELLS, NATURAL; OXIDANTS; PHENOTYPE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032528257     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199807150-00011     Document Type: Article

References (71)

1. Mocarski ES Jr. Cytomegalovirus biology and replication. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpesviruses. New York: Raven Press, 1993: 173.
2. Alford CA, Britt WJ. Cytomegalovirus. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpesviruses. New York: Raven Press, 1993: 227.
3. Beschorner WE, Hutchins GM, Burns WH, Saral R, Tutschka PJ, Santos GW. Cytomegalovirus pneumonia in bone marrow transplant recipients: miliary and diffuse patterns. Am Rev Respir Dis 1980; 122: 107.
4. Ramsey PG, Rubin RH, Tolkoff-Rubin NE, Cosimi AB, Russell PS, Greene R. The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management. Medicine 1980; 59: 206.
5. Foucar E, Mukai K, Foucar K, Sutherland DER, Van Buren CT. Colon ulceration in lethal Cytomegalovirus infection. Am J Clin Pathol 1981; 76: 788.
6. Spencer GD, Shulman HM, Myerson D, Thomas ED, McDonald GB. Diffuse intestinal ulceration after marrow transplantation: a clinicopathologic study of 13 patients. Hum Pathol 1986; 17: 621.
7. Paya CV, Hermans PE, Wiesner RH, et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989; 160: 752.
8. Augsburger JJ, Henry RY. Retinal aneurysms in adult cytomegalovirus retinitis. Am J Opthalmol 1978; 86: 794.
9. Peterson PK, Balfour HH Jr, Marker SC, Fryd DS, Howard RJ, Simmons RL. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine 1980; 59: 283.
10. Lopez C, Simmons RL, Mauer SM, Najarian JS, Good RA. Association of renal allograft rejection with virus infections. Am J Med 1974; 56: 280.
11. von Willebrand E, Pettersson E, Ahonen J, Häyry P. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986; 42: 364.
12. Gulizia JM, Kandolf R, Kendall TJ, et al. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol 1995; 147: 461.
13. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
14. Normann SJ, Salomon DR, Leelachaikul P, et al. Acute vascular rejection of the coronary arteries in human heart transplantation: pathology and correlations with immunosuppression and cytomegalovirus infection. J Heart Lung Transplant 1991; 10: 674.
15. Everett JP, Hershberger RE, Norman DJ, et al. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 1992; 11: S133.
16. Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant 1989; 8: 349.
17. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
18. Fuggle SV, Sanderson JB, Gray DWR, Richardson A, Morris PJ. Variation in expression of endothelial adhesion molecules in pretransplant and transplanted kidneys: correlation with intragraft events. Transplantation 1993; 55: 117.
19. Salomon RN, Hughes CCW, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 1991; 138: 791.
20. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427.
21. Roberts WH, Sneddon JM, Waldman WJ, Stephens RE. Cytomegalovirus infection of gastrointestinal endothelium demonstrated by simultaneous nucleic acid hybridization and immunohistochemistry. Arch Pathol Lab Med 1989; 113: 461.
22. Ho DD, Rota TR, Andrews CA, Hirsch MS. Replication of human cytomegalovirus in endothelial cells. J Infect Dis 1984; 150: 956.
23. Bruggeman CA, Debie WHM, Muller AD, Schutte B, van Dam-Mieras MCE. Cytomegalovirus alters the von Willebrand factor content in human endothelial cells. Thromb Haemostasis 1988; 59: 264.
24. Waldman WJ, Sneddon JM, Stephens RE, Roberts WH. Enhanced endothelial cytopathogenicity induced by a cytomegalovirus strain propagated in endothelial cells. J Med Virol 1989; 28: 223.
25. Waldman WJ, Adams PW, Orosz CG, Sedmak DD. T lymphocyte activation by cytomegalovirus-infected, allogeneic cultured human endothelial cells. Transplantation 1992; 54: 887.
26. + T cells. Transplantation 1993; 56: 1504.
27. Waldman WJ, Knight DA. Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cytomegalovirus-activated T cells. Am J Pathol 1996; 148: 105.
28. Vaccaro PS, Joseph LB, Titterington L, Stephens RE. Methods for the initiation and maintenance of human endothelial cell culture. Vasc Surg 1987; 21: 391.
29. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745.
30. Gimbrone MA Jr, Cotran RS, Folkman J. Human vascular endothelial cells in culture: growth and DNA synthesis. J Cell Biol 1974; 60: 673.
31. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA 1979; 76: 5674.
32. Sharma HM, Kauffman EM, Conrad CM. An improved immunoperoxidase technique using horseradish peroxidase avidin D. Lab Med 1989; 20: 109.
33. Sedmak DD, Roberts WH, Stephens RE, et al. Inability of cytomegalovirus infection of cultured endothelial cells to induce HLA class II antigen expression. Transplantation 1990; 49: 458.
34. Waldman WJ, Roberts WH, Davis DH, Williams MV, Sedmak DD, Stephens RE. Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells. Arch Virol 1991; 117: 143.
35. Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21: 77.
36. Clouse K, Adams P, Sheridan J, Orosz C. Rapid method for purification of human T lymphocytes for further functional studies. J Immunol Methods 1987; 105: 253.
37. Eriksson B, Oberg B, Wahren B. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta 1982; 696: 115.
38. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981; 126: 1614.
39. Confer DL, Vercellotti GM, Kotasek D, Goodman JL, Ochoa A, Jacob HS. Herpes simplex virus-infected cells disarm killer lymphocytes. Proc Natl Acad Sci USA 1990; 87: 3609.
40. Sedmak DD, Guglielmo AM, Knight DA, Birmingham DJ, Huang EH, Waldman WJ. Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. Am J Pathol 1994; 144: 683.
41. Sedmak DD, Knight DA, Vook NA, Waldman WJ. Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation 1994; 58: 1379.
42. Knight, DA, Waldman WJ, Sedmak DD. Human cytomegalovirus does not induce HLA class II expression on arterial endothelial cells. Transplantation 1997; 63: 1366.
43. Waldman WJ, Knight DA, Huang EH. An in vitro model of T cell activation by autologous cytomegalovirus (CMV)-infected human adult endothelial cells: contribution of CMV-enhanced endothelial ICAM-1. J Immunol 1998; 160: 3143.
44. Wills MR, Carmichael AJ, Mynard K, et al. The human cytoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70: 7569.
45. Ljunggren HG, Karre K. In search of the "missing self": MHC molecules and NK recognition. Immunol Today 1990; 11: 237.
46. Hirschberg H, Bergh OJ, Thorsby E. Antigen-presenting properties of human vascular endothelial cells. J Exp Med 1980; 152: 249s.
47. Hughes CCW, Savage COS, Pober JS. The endothelial cell as a regulator of T cell function. Immunol Rev 1990; 117: 85.
48. Jutila MA, Berg EL, Kishimoto TK, et al. Inflammation-induced endothelial cell adhesion to lymphocytes, neutrophils, and monocytes. Transplantation 1989; 48: 727.
49. Tanaka H, Sukhova GK, Swanson SJ, Cybulsky MI, Schoen FJ, Libby P. Endothelial and smooth muscle cells express leukocyte adhesion molecules heterogeneously during acute rejection of rabbit cardiac allografts. Am J Pathol 1994; 144: 938.
50. Adams PW, Lee HS, Waldman WJ, et al. Alloantigenicity of human endothelial cells. I. Frequency and phenotype of human helper T lymphocytes that can react to allogeneic endothelial cells. J Immunol 1992; 148: 3753.
51. Murray N, McMichael A. Antigen presentation in virus infection. Curr Opin Immunol 1992; 4: 401.
52. Quinnan GV Jr, Kirmani N, Rook AH, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982; 307: 6.
53. Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 1987; 61: 3102.
54. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373.
55. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238.
56. 2-microglobulin on the surface of cells infected with cytomegalovirus. J Gen Virol 1992; 73: 2395.
57. Beersma MFC, Bijlmakers MJE, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 1993; 151: 4455.
58. Gilbert MJ, Riddell SR, Li CR, Greenberg PD. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 1993; 67: 3461.
59. Warren AP, Ducroq DH, Lehner PJ, Borysiewicz LK. Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J Virol 1994; 68: 2822.
60. Zhu H, Shen Y, Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol 1995; 69: 7960.
61. Kovacs A, Weber ML, Burns LJ, Jacob HS, Vercellotti GM. Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells. Am J Pathol 1996; 149: 1531.
62. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988; 331: 269.
63. 2 microglobulin. Nature 1990; 347: 770.
64. Fahnestock ML, Johnson JL, Feldman RMR, Neveu JM, Lane WS, Bjorkman PJ. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 1995; 3: 583.
65. Reyburn HT, Mandelboim O, Valés-Gómez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997; 386: 514.
66. Farrell HE, Vally H, Lynch DM, et al. Inhibition of natural killer cells by a cytomegalovirus MHC homolog in vivo. Nature 1997 386: 510.
67. Schrier RD, Nelson JA, Oldstone MBA. Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science 1985; 230: 1048.
68. Saltzman RL, Quirk MR, Jordan MC. Disseminated cytomegalovirus infection: molecular analysis of virus and leukocyte interactions in viremia. J Clin Invest 1988; 81: 75.
69. Gerna G, Zipeto D, Percivalle E, et al. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis 1992; 166: 1236.
70. Waldman WJ, Knight DA, Huang EH, Sedmak DD. Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: an in vitro model. J Infect Dis 1995; 171: 263.
71. Leong CC, Chapman TL, Bjorkman PJ, et al. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med 1998; 187: 1681.